Bioscience company
Appears in 1 story · Last updated Nov 11, 2026
Acquired by Solventum in December 2025
The U.S. Food and Drug Administration cleared Solventum to use its Restrata synthetic tissue matrix with its V.A.C. negative pressure wound therapy on October 19, 2026, the first clearance combining the two. Clinicians can place a fully synthetic, resorbable scaffold under a vacuum dressing that stays on for up to seven days.
Updated 3 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
